Professor Gill Harinder Singh Harry is currently Clinical Associate Professor at the Department of Medicine, School of Clinical Medicine, the University of Hong Kong. He graduated from the University of Hong Kong in 2006 and joined the Department of Medicine, Queen Mary Hospital in July 2007. He joined the University of Hong Kong as Clinical Assistant Professor in July 2014 and completed his training in Haematology and Haematological Oncology, and Advanced Internal Medicine in 2013 and 2014, respectively. He also underwent training in Haematopathology at the Department of Pathology, Queen Mary Hospital from 2017 to 2019 and was conferred Fellow of The Royal College of Pathologists in February 2019. He completed his doctorate degree in 2019 focusing on the genomics of myeloproliferative neoplasms. He was conferred First Fellow in Genetics and Genomics (Medicine) by the Hong Kong College of Physicians in 2023. He is the service-lead for acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) in Queen Mary Hospital, Hong Kong.

One of his key research areas since 2010 is the application of oral arsenic trioxide in the treatment of acute promyelocytic leukaemia (APL) and other haematological malignancies. Important practice-changing observations were made. He steered the research and development, and the clinical use of the Good Manufacturing Practice (GMP) grade oral arsenic trioxide (Arsenol ®), the first GMP grade oral formulation of arsenic trioxide worldwide. Based on his research findings, oral arsenic trioxide was granted orphan drug designation (ODD) by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in December 2024 and Investigational New Drug (IND) designation by the US FDA in January 2025.

Professor Gill also leads research on MDS and MPN with specific focus on molecular alterations and novel therapeutics in these disorders. He is currently leading studies on the genomics of clonal haematopoiesis, MDS, secondary AML and MPN. 

He is one of the founding members and directors of the Asian Myeloid Working Group leading key regional studies on myeloid malignancies in Asia including the Asian MDS Genomics Registry, the APL Asian Consortium Study, and the Asian MPN Registry.

HKU Scholars Hub

1. Acute promyelocytic leukaemia
2. Acute myeloid leukaemia
3. Myelodysplastic Syndrome
4. Myeloproliferative Neoplasm
5. Applications of oral arsenic trioxide in haematological malignancies
6. Clonal haematopoiesis
7. Germline predisposition to myeloid malignancies

1. Gill H*, Yacoub A, Gerds AT, et al. The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study. Blood Advances. 2026 Apr 29.
2. Gill H*, Au L, Yim RL, et al. Ropeginterferon alfa-2b for pre-fibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction. Blood Advances. 2026 Mar 24.
3. Gill H*, Palandri F, Ross DM, et al. Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia. Blood Advances. 2026 Mar 3.
4. Mesa R, Gill H, Zhang L, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. The Lancet Haematology. 2025 Nov 1;12(11):e862-75.
5. Kirito K, Choi CW, Hein T, Hou HA, Jung CW, Kwong YL, Leung GM, Ooi MG, Rojnuckarin P, Ross DM, Shih LY, Takenaka K, Teo WZY, Gill H*. Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance. JCO Oncology Practice. 2025 Jul.
6. Gill H*, Yim R, Lee P, et al. A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia. Blood Cancer Journal. 2025 Jul 31;15(1):128.
7. Gill H*, Raghupathy R, Hou HA, et al. Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome. Blood Advances. 2025 Feb 25;9(4):862-76.
8. Gill H*, Leung GM, Kwong YL. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations. Hematology. 2023;2023(1):667-75.
9. Gill H*, Raghupathy R, Lee CY, et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC cancer. 2023; 23(1):141.
10. Gill H*, Yung Y, Chu HT, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv, 2021;5(14):2829-38. 
11. Gill H, Yim R, Kumana CR, Tse E, Kwong YL. Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators. Cancer, 2020; 126(14): 3244-3254. 
12. Gill H, Kumana CR, Yim R, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. Cancer, 2019; 125(17): 3001-3012.
13. Gill H, Yim R, Lee HKK, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based re-induction and maintenance regimens: A 15-year prospective study. Cancer, 2018; 124(11): 2316-26.
14. Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Science Trans Med. 2016;8(359):359ra129-.
15. Gill H, Man CH, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY. Azacitidine as post-remission consolidation for sorafenib induced remission of Fms-Like Tyrosine Kinase-2 internal tandem duplication positive acute myeloid leukemia. Haematologica, 2015; 100(7):250-3.
16. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol, 2014; 32(33): 3736-43. 
17. Gill H, Au WY, Cheung WW, Kwong YL. Oral arsenic trioxide based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol, 2014; 25(7): 1391-7.
18. Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood, 2014; 123 (16): 2530-9.
    
    *: corresponding author